JP2021513998A - 鏡像異性体的に濃縮された、または鏡像異性体的に純粋なブプロピオンの剤形 - Google Patents
鏡像異性体的に濃縮された、または鏡像異性体的に純粋なブプロピオンの剤形 Download PDFInfo
- Publication number
- JP2021513998A JP2021513998A JP2020544420A JP2020544420A JP2021513998A JP 2021513998 A JP2021513998 A JP 2021513998A JP 2020544420 A JP2020544420 A JP 2020544420A JP 2020544420 A JP2020544420 A JP 2020544420A JP 2021513998 A JP2021513998 A JP 2021513998A
- Authority
- JP
- Japan
- Prior art keywords
- bupropion
- dosage form
- administered
- dextromethorphan
- human
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- SNPPWIUOZRMYNY-SECBINFHSA-N C[C@H](C(c1cc(Cl)ccc1)=O)NC(C)(C)C Chemical compound C[C@H](C(c1cc(Cl)ccc1)=O)NC(C)(C)C SNPPWIUOZRMYNY-SECBINFHSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Addiction (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Rheumatology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022124557A JP2022153638A (ja) | 2018-02-23 | 2022-08-04 | 鏡像異性体的に濃縮された、または鏡像異性体的に純粋なブプロピオンの剤形および方法 |
| JP2024041381A JP2024075655A (ja) | 2018-02-23 | 2024-03-15 | 鏡像異性体的に濃縮された、または鏡像異性体的に純粋なブプロピオンの剤形および方法 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862634718P | 2018-02-23 | 2018-02-23 | |
| US62/634,718 | 2018-02-23 | ||
| US201962794469P | 2019-01-18 | 2019-01-18 | |
| US62/794,469 | 2019-01-18 | ||
| US201962809480P | 2019-02-22 | 2019-02-22 | |
| US62/809,480 | 2019-02-22 | ||
| PCT/US2019/019445 WO2019165379A1 (en) | 2018-02-23 | 2019-02-25 | Dosage forms and methods for enantiomerically enriched or pure bupropion |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022124557A Division JP2022153638A (ja) | 2018-02-23 | 2022-08-04 | 鏡像異性体的に濃縮された、または鏡像異性体的に純粋なブプロピオンの剤形および方法 |
| JP2024041381A Division JP2024075655A (ja) | 2018-02-23 | 2024-03-15 | 鏡像異性体的に濃縮された、または鏡像異性体的に純粋なブプロピオンの剤形および方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JP2021513998A true JP2021513998A (ja) | 2021-06-03 |
Family
ID=67688503
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020544420A Pending JP2021513998A (ja) | 2018-02-23 | 2019-02-25 | 鏡像異性体的に濃縮された、または鏡像異性体的に純粋なブプロピオンの剤形 |
| JP2022124557A Pending JP2022153638A (ja) | 2018-02-23 | 2022-08-04 | 鏡像異性体的に濃縮された、または鏡像異性体的に純粋なブプロピオンの剤形および方法 |
| JP2024041381A Pending JP2024075655A (ja) | 2018-02-23 | 2024-03-15 | 鏡像異性体的に濃縮された、または鏡像異性体的に純粋なブプロピオンの剤形および方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022124557A Pending JP2022153638A (ja) | 2018-02-23 | 2022-08-04 | 鏡像異性体的に濃縮された、または鏡像異性体的に純粋なブプロピオンの剤形および方法 |
| JP2024041381A Pending JP2024075655A (ja) | 2018-02-23 | 2024-03-15 | 鏡像異性体的に濃縮された、または鏡像異性体的に純粋なブプロピオンの剤形および方法 |
Country Status (19)
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2022153638A (ja) * | 2018-02-23 | 2022-10-12 | アクスサム セラピューティクス インコーポレイテッド | 鏡像異性体的に濃縮された、または鏡像異性体的に純粋なブプロピオンの剤形および方法 |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11291639B2 (en) | 2018-09-20 | 2022-04-05 | Axsome Therapeutics, Inc. | Dosage forms and methods for enantiomerically enriched or pure bupropion |
| US11660274B2 (en) | 2018-09-20 | 2023-05-30 | Axsome Therapeutics, Inc. | Dosage forms and methods for enantiomerically enriched or pure bupropion |
| US11660273B2 (en) | 2018-09-20 | 2023-05-30 | Axsome Therapeutics, Inc. | Dosage forms and methods for enantiomerically enriched or pure bupropion |
| CN114423417A (zh) * | 2019-09-20 | 2022-04-29 | 艾克萨姆治疗公司 | 用于对映体富集的或纯的安非他酮的剂型和方法 |
| US20250073188A1 (en) | 2020-06-05 | 2025-03-06 | Antecip Bioventures Ii Llc | Compounds and combinations thereof for treating neurological and psychiatric conditions |
| US11717518B1 (en) | 2022-06-30 | 2023-08-08 | Antecip Bioventures Ii Llc | Bupropion dosage forms with reduced food and alcohol dosing effects |
| US12036191B1 (en) | 2022-06-30 | 2024-07-16 | Antecip Bioventures Ii Llc | Treatment of poor metabolizers of dextromethorphan with a combination of bupropion and dextromethorphan |
| US12156914B2 (en) | 2022-06-30 | 2024-12-03 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising bupropion and cysteine |
| US11730706B1 (en) | 2022-07-07 | 2023-08-22 | Antecip Bioventures Ii Llc | Treatment of depression in certain patient populations |
| KR20250114110A (ko) | 2022-11-28 | 2025-07-28 | 안테씨프 바이오벤쳐스 투 엘엘씨 | 약물 활성의 조절제로서의 부프로피온 |
| WO2025259728A1 (en) * | 2024-06-13 | 2025-12-18 | Antecip Bioventures Ii Llc | Compounds and combinations thereof for treating neurological and psychiatric conditions |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2003529563A (ja) * | 2000-02-22 | 2003-10-07 | セプラコア インコーポレーテッド | ビュープロピオン代謝産物並びにその合成および使用方法 |
| WO2012118562A1 (en) * | 2011-03-02 | 2012-09-07 | Rhine Pharmaceuticals, Llc | Compositions and methods for treating depression, adhd and other central nervous system disorders employing novel bupropion compounds, and methods for production and use of novel bupropion compounds and formulations |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999038502A1 (en) * | 1998-01-29 | 1999-08-05 | Sepracor Inc. | Pharmaceutical uses of optically pure (+)-bupropion |
| CN1819821B (zh) * | 2003-08-08 | 2010-10-13 | 拜奥维尔实验室国际股份有限公司 | 盐酸安非他酮的改良释放片剂 |
| EP3981403A1 (en) * | 2013-11-05 | 2022-04-13 | Antecip Bioventures II LLC | Compositions and methods comprising bupropion or related compounds and dextromethorphan |
| US9474731B1 (en) * | 2013-11-05 | 2016-10-25 | Antecip Bioventures Ii Llc | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects |
| US10080727B2 (en) * | 2013-11-05 | 2018-09-25 | Antecip Bioventures Ii Llc | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects |
| MX2013014166A (es) * | 2013-12-03 | 2015-06-10 | Inst De Investigacion En Quimica Aplic S A De C V | Enantiomeros activos y sus sales para el tratamiento de la obesidad. |
| US9732031B2 (en) * | 2013-12-20 | 2017-08-15 | Deuterx, Llc | Methods of treating neurological and other disorders using enantiopure deuterium-enriched bupropion |
| CA3092076A1 (en) * | 2018-02-23 | 2019-08-29 | Axsome Therapeutics, Inc. | Dosage forms and methods for enantiomerically enriched or pure bupropion |
-
2019
- 2019-02-25 CA CA3092076A patent/CA3092076A1/en active Pending
- 2019-02-25 CN CN201980026874.5A patent/CN112087999A/zh active Pending
- 2019-02-25 MX MX2020008704A patent/MX2020008704A/es unknown
- 2019-02-25 NZ NZ767378A patent/NZ767378A/en unknown
- 2019-02-25 MA MA051914A patent/MA51914A/fr unknown
- 2019-02-25 SG SG11202008056SA patent/SG11202008056SA/en unknown
- 2019-02-25 AU AU2019223187A patent/AU2019223187B2/en active Active
- 2019-02-25 IL IL276871A patent/IL276871B2/en unknown
- 2019-02-25 KR KR1020247017593A patent/KR20240091043A/ko not_active Ceased
- 2019-02-25 WO PCT/US2019/019445 patent/WO2019165379A1/en not_active Ceased
- 2019-02-25 CR CR20200415A patent/CR20200415A/es unknown
- 2019-02-25 JP JP2020544420A patent/JP2021513998A/ja active Pending
- 2019-02-25 KR KR1020207027256A patent/KR20210003091A/ko not_active Ceased
- 2019-02-25 BR BR112020017179-4A patent/BR112020017179A2/pt not_active Application Discontinuation
- 2019-02-25 CN CN202510967625.3A patent/CN120827545A/zh active Pending
- 2019-02-25 KR KR1020237017449A patent/KR20230075531A/ko not_active Ceased
- 2019-02-25 MY MYPI2020004315A patent/MY202993A/en unknown
- 2019-02-25 EP EP19756920.5A patent/EP3755312A4/en active Pending
- 2019-02-25 IL IL313368A patent/IL313368A/en unknown
- 2019-02-25 PE PE2020001272A patent/PE20211752A1/es unknown
-
2020
- 2020-08-20 MX MX2023009281A patent/MX2023009281A/es unknown
- 2020-08-21 NI NI202000056A patent/NI202000056A/es unknown
- 2020-08-21 CL CL2020002166A patent/CL2020002166A1/es unknown
- 2020-09-23 EC ECSENADI202060179A patent/ECSP20060179A/es unknown
-
2022
- 2022-06-27 AU AU2022204521A patent/AU2022204521B2/en active Active
- 2022-08-04 JP JP2022124557A patent/JP2022153638A/ja active Pending
-
2024
- 2024-03-15 JP JP2024041381A patent/JP2024075655A/ja active Pending
- 2024-08-17 AU AU2024205858A patent/AU2024205858A1/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2003529563A (ja) * | 2000-02-22 | 2003-10-07 | セプラコア インコーポレーテッド | ビュープロピオン代謝産物並びにその合成および使用方法 |
| WO2012118562A1 (en) * | 2011-03-02 | 2012-09-07 | Rhine Pharmaceuticals, Llc | Compositions and methods for treating depression, adhd and other central nervous system disorders employing novel bupropion compounds, and methods for production and use of novel bupropion compounds and formulations |
Non-Patent Citations (1)
| Title |
|---|
| J CLIN PHARMACOL, vol. 48, JPN6021032200, 2008, pages 464 - 474, ISSN: 0004744663 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2022153638A (ja) * | 2018-02-23 | 2022-10-12 | アクスサム セラピューティクス インコーポレイテッド | 鏡像異性体的に濃縮された、または鏡像異性体的に純粋なブプロピオンの剤形および方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| CA3092076A1 (en) | 2019-08-29 |
| PE20211752A1 (es) | 2021-09-06 |
| CN120827545A (zh) | 2025-10-24 |
| AU2019223187A1 (en) | 2020-09-17 |
| NI202000056A (es) | 2021-01-11 |
| IL276871A (en) | 2020-10-29 |
| MY202993A (en) | 2024-05-31 |
| KR20240091043A (ko) | 2024-06-21 |
| IL276871B2 (en) | 2024-11-01 |
| MX2020008704A (es) | 2020-12-07 |
| AU2024205858A1 (en) | 2024-09-05 |
| IL313368A (en) | 2024-08-01 |
| WO2019165379A1 (en) | 2019-08-29 |
| ECSP20060179A (es) | 2020-12-31 |
| CN112087999A (zh) | 2020-12-15 |
| MX2023009281A (es) | 2023-08-17 |
| EP3755312A1 (en) | 2020-12-30 |
| BR112020017179A2 (pt) | 2020-12-22 |
| KR20230075531A (ko) | 2023-05-31 |
| AU2022204521A1 (en) | 2022-07-21 |
| CL2020002166A1 (es) | 2020-10-23 |
| AU2022204521B2 (en) | 2024-09-05 |
| NZ767378A (en) | 2024-03-22 |
| JP2024075655A (ja) | 2024-06-04 |
| AU2019223187B2 (en) | 2022-07-28 |
| CR20200415A (es) | 2021-02-03 |
| MA51914A (fr) | 2020-12-30 |
| SG11202008056SA (en) | 2020-09-29 |
| IL276871B1 (en) | 2024-07-01 |
| KR20210003091A (ko) | 2021-01-11 |
| EP3755312A4 (en) | 2022-03-16 |
| JP2022153638A (ja) | 2022-10-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20210196704A1 (en) | Dosage forms and methods for enantiomerically enriched or pure bupropion | |
| US20210177834A1 (en) | Dosage forms and methods for enantiomerically enriched or pure bupropion | |
| US20190216800A1 (en) | Dosage forms and methods for enantiomerically enriched or pure bupropion | |
| US12377091B2 (en) | Compounds and combinations thereof for treating neurological and psychiatric conditions | |
| US20190216801A1 (en) | Dosage forms and methods for enantiomerically enriched or pure bupropion | |
| AU2022204521B2 (en) | Dosage forms and methods for enantiomerically enriched or pure bupropion | |
| US11344544B2 (en) | Bupropion as a modulator of drug activity | |
| US20220313689A1 (en) | Bupropion as a modulator of drug activity | |
| JP2022516361A (ja) | うつ病の治療のためのデキストロメトルファンおよびブプロピオンの組み合わせ | |
| US20210106546A1 (en) | Bupropion as a modulator of drug activity | |
| US20200093761A1 (en) | Dosage forms and methods for enantiomerically enriched or pure bupropion | |
| US12433884B2 (en) | Compounds and combinations thereof for treating neurological and psychiatric conditions | |
| US11179352B2 (en) | Dosage forms and methods for enantiomerically enriched or pure bupropion | |
| US11433035B2 (en) | Dosage forms and methods for enantiomerically enriched or pure bupropion | |
| US12102606B2 (en) | Dosage forms and methods for enantiomerically enriched or pure bupropion | |
| JP2024059812A (ja) | 鏡像異性体的に濃縮された、または純粋なブプロピオンの剤形および方法 | |
| US20260014142A1 (en) | Dosage forms and methods for enantiomerically enriched or pure bupropion | |
| US20220249405A1 (en) | Dosage forms and methods for enantiomerically enriched or pure bupropion | |
| HK40043597A (en) | Dosage forms and methods for enantiomerically enriched or pure bupropion | |
| BR122026004011A2 (pt) | Forma de dosagem e uso de (s)-bupropiona | |
| HK40066587A (en) | Dosage forms and methods for enantiomerically enriched or pure bupropion |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20201014 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20201014 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20210824 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20220405 |
|
| C60 | Trial request (containing other claim documents, opposition documents) |
Free format text: JAPANESE INTERMEDIATE CODE: C60 Effective date: 20220804 |
|
| C116 | Written invitation by the chief administrative judge to file amendments |
Free format text: JAPANESE INTERMEDIATE CODE: C116 Effective date: 20220816 |
|
| C22 | Notice of designation (change) of administrative judge |
Free format text: JAPANESE INTERMEDIATE CODE: C22 Effective date: 20220816 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20220809 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20231215 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20240117 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20240215 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240315 |